Equities Analysts Offer Predictions for ZVRA Q1 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Roth Capital upped their Q1 2025 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a report released on Tuesday, March 11th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of ($0.17) for the quarter, up from their previous forecast of ($0.27). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. Roth Capital also issued estimates for Zevra Therapeutics’ Q2 2025 earnings at ($0.08) EPS, Q4 2025 earnings at $0.08 EPS, FY2025 earnings at ($0.10) EPS, FY2026 earnings at $0.81 EPS, FY2027 earnings at $1.38 EPS and FY2028 earnings at $1.79 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.28). The business had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $8.93 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%.

Several other research firms also recently weighed in on ZVRA. Canaccord Genuity Group boosted their price target on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research note on Thursday. Finally, Guggenheim lifted their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $22.14.

Zevra Therapeutics Stock Up 0.3 %

ZVRA opened at $7.94 on Friday. Zevra Therapeutics has a 52 week low of $4.20 and a 52 week high of $9.76. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The business’s fifty day simple moving average is $7.93 and its 200 day simple moving average is $8.14. The stock has a market cap of $423.81 million, a PE ratio of -4.03 and a beta of 1.98.

Institutional Investors Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. MetLife Investment Management LLC grew its position in shares of Zevra Therapeutics by 8.1% during the third quarter. MetLife Investment Management LLC now owns 22,866 shares of the company’s stock valued at $159,000 after purchasing an additional 1,717 shares in the last quarter. IFG Advisors LLC raised its position in Zevra Therapeutics by 10.0% in the 4th quarter. IFG Advisors LLC now owns 29,050 shares of the company’s stock worth $242,000 after purchasing an additional 2,650 shares during the period. Invesco Ltd. raised its holdings in shares of Zevra Therapeutics by 19.6% in the fourth quarter. Invesco Ltd. now owns 18,384 shares of the company’s stock worth $153,000 after buying an additional 3,007 shares during the period. Corebridge Financial Inc. lifted its position in shares of Zevra Therapeutics by 16.9% during the fourth quarter. Corebridge Financial Inc. now owns 26,294 shares of the company’s stock worth $219,000 after purchasing an additional 3,801 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its holdings in Zevra Therapeutics by 36.1% during the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock valued at $138,000 after buying an additional 4,384 shares in the last quarter. 35.03% of the stock is owned by institutional investors.

Insider Transactions at Zevra Therapeutics

In other Zevra Therapeutics news, EVP Joshua Schafer sold 10,500 shares of the stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $82,530.00. Following the transaction, the executive vice president now owns 29,486 shares of the company’s stock, valued at approximately $231,759.96. This represents a 26.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $481,605.78. Following the completion of the transaction, the chief executive officer now directly owns 222,060 shares in the company, valued at approximately $1,745,391.60. The trade was a 21.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 85,773 shares of company stock worth $674,176 over the last three months. 2.40% of the stock is currently owned by company insiders.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.